首页> 外文期刊>ACS medicinal chemistry letters >N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors
【24h】

N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors

机译:N-(3-乙炔基-2,4-二氟苯基)磺酰胺衍生物作为选择性Raf抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

A series of N-(3-ethynyl-2,4-difluorophenyl)sulfonamides were identified as new selective Raf inhibitors. The compounds potently inhibit B-Raf(V600E) with low nanomolar IC50 values and exhibit excellent target specificity in a selectivity profiling investigation against 468 kinases. They strongly suppress proliferation of a panel of human cancer cell lines and patient-derived melanoma cells with B-Raf(V600E) mutation while being significantly less potent to the cells with B-Raf(WT). The compounds also display favorable pharmacokinetic properties with a preferred example (3s) demonstrating significant in vivo antitumor efficacy in a xenograft mouse model of B-Raf(V600E) mutated Colo205 human colorectal cancer cells, supporting it as a promising lead compound for further anticancer drug discovery.
机译:一系列N-(3-乙炔基-2,4-二氟苯基)磺酰胺被确定为新型的选择性Raf抑制剂。这些化合物可有效抑制具有低纳摩尔IC50值的B-Raf(V600E),并在针对468种激酶的选择性分析中显示出色的靶标特异性。它们强烈抑制具有B-Raf(V600E)突变的一组人类癌细胞系和患者源性黑色素瘤细胞的增殖,而对具有B-Raf(WT)的细胞的效力明显较低。该化合物还显示出良好的药代动力学特性,其中一个优选的实施例(3s)在B-Raf(V600E)突变的Colo205人结直肠癌细胞的异种移植小鼠模型中显示出显着的体内抗肿瘤功效,从而支持其作为进一步的抗癌药物的有希望的先导化合物发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号